Spero Therapeutics, Inc.
(NASDAQ : SPRO)

( )
SPRO After-Hours: () as of PM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Pharmaceuticals Major
symbolcompany%chnglast%shortavg$volume
JNJJohnson & Johnson -1.81%175.590.7%$1405.98m
PFEPfizer Inc. -1.83%50.400.9%$1327.23m
ABBVAbbVie, Inc. -1.44%152.551.9%$1169.95m
BMYBristol-Myers Squibb Co. -1.52%77.031.0%$1169.89m
MRKMerck & Co., Inc. -1.02%92.050.7%$1097.17m
LLYEli Lilly & Co. -1.98%295.431.1%$859.74m
AZNAstraZeneca Plc -3.53%63.321.0%$489.96m
BHVNBiohaven Pharmaceutical Holding Co. Ltd. 0.09%141.900.0%$438.60m
VERUVeru, Inc. -3.78%15.010.0%$363.86m
NVSNovartis AG -0.27%87.680.2%$229.58m
GSKGlaxoSmithKline Plc -2.42%43.630.2%$222.90m
HZNPHorizon Therapeutics Plc -4.82%88.425.4%$193.67m
SGENSeagen Inc. -2.42%143.005.7%$174.55m
NVONovo Nordisk A/S -2.61%103.560.1%$171.61m
VTRSViatris, Inc. -1.74%11.270.0%$153.78m

Company Profile

Spero Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on identifying, developing, and commercializing treatments involving bacterial infections, including multi-drug resistant bacterial infections, and rare diseases Its pipeline product candidates include Tebipenem HBr, SPR720, and SPR206. The company was founded by Ankit A. Mahadevia and Laurence Rahme in April 2013 and is headquartered in Cambridge, MA.